420 related articles for article (PubMed ID: 32816920)
21. Codelivery of HIF-1α siRNA and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression.
Izadi S; Moslehi A; Kheiry H; Karoon Kiani F; Ahmadi A; Masjedi A; Ghani S; Rafiee B; Karpisheh V; Hajizadeh F; Atyabi F; Assali A; Mirzazadeh Tekie FS; Namdar A; Ghalamfarsa G; Sojoodi M; Jadidi-Niaragh F
Pharm Res; 2020 Sep; 37(10):196. PubMed ID: 32944844
[TBL] [Abstract][Full Text] [Related]
22. JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice.
Song X; Zhu S; Xie Y; Liu J; Sun L; Zeng D; Wang P; Ma X; Kroemer G; Bartlett DL; Billiar TR; Lotze MT; Zeh HJ; Kang R; Tang D
Gastroenterology; 2018 Apr; 154(5):1480-1493. PubMed ID: 29248440
[TBL] [Abstract][Full Text] [Related]
23. PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC.
Wang X; Li X; Wei X; Jiang H; Lan C; Yang S; Wang H; Yang Y; Tian C; Xu Z; Zhang J; Hao J; Ren H
Signal Transduct Target Ther; 2020 Apr; 5(1):38. PubMed ID: 32300119
[TBL] [Abstract][Full Text] [Related]
24. A New Oxadiazole-Based Topsentin Derivative Modulates Cyclin-Dependent Kinase 1 Expression and Exerts Cytotoxic Effects on Pancreatic Cancer Cells.
Pecoraro C; Parrino B; Cascioferro S; Puerta A; Avan A; Peters GJ; Diana P; Giovannetti E; Carbone D
Molecules; 2021 Dec; 27(1):. PubMed ID: 35011251
[TBL] [Abstract][Full Text] [Related]
25. Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy.
Koikawa K; Kibe S; Suizu F; Sekino N; Kim N; Manz TD; Pinch BJ; Akshinthala D; Verma A; Gaglia G; Nezu Y; Ke S; Qiu C; Ohuchida K; Oda Y; Lee TH; Wegiel B; Clohessy JG; London N; Santagata S; Wulf GM; Hidalgo M; Muthuswamy SK; Nakamura M; Gray NS; Zhou XZ; Lu KP
Cell; 2021 Sep; 184(18):4753-4771.e27. PubMed ID: 34388391
[TBL] [Abstract][Full Text] [Related]
26. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer.
Rajput S; Khera N; Guo Z; Hoog J; Li S; Ma CX
Oncotarget; 2016 Aug; 7(35):56864-56875. PubMed ID: 27486754
[TBL] [Abstract][Full Text] [Related]
28. Genetic Deletion of Galectin-3 Inhibits Pancreatic Cancer Progression and Enhances the Efficacy of Immunotherapy.
Yang D; Sun X; Moniruzzaman R; Wang H; Citu C; Zhao Z; Wistuba II; Wang H; Maitra A; Chen Y
Gastroenterology; 2024 Jul; 167(2):298-314. PubMed ID: 38467382
[TBL] [Abstract][Full Text] [Related]
29. Pivotal antitumor role of the immune checkpoint molecule B7-H1 in pancreatic cancer.
Bazhin AV; von Ahn K; Fritz J; Bunge H; Maier C; Isayev O; Neff F; Siveke JT; Karakhanova S
Oncoimmunology; 2022; 11(1):2043037. PubMed ID: 35251770
[TBL] [Abstract][Full Text] [Related]
30. Dinaciclib exerts a tumor-suppressing effect via β-catenin/YAP axis in pancreatic ductal adenocarcinoma.
Li Y; Zheng Z; Xiao L; Chen Y; Liu X; Long D; Chai L; Li Y; Tan C
Anticancer Drugs; 2024 Feb; 35(2):140-154. PubMed ID: 37694833
[TBL] [Abstract][Full Text] [Related]
31. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
32. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
[TBL] [Abstract][Full Text] [Related]
33. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215
[TBL] [Abstract][Full Text] [Related]
34. Immune-regulated IDO1-dependent tryptophan metabolism is source of one-carbon units for pancreatic cancer and stellate cells.
Newman AC; Falcone M; Huerta Uribe A; Zhang T; Athineos D; Pietzke M; Vazquez A; Blyth K; Maddocks ODK
Mol Cell; 2021 Jun; 81(11):2290-2302.e7. PubMed ID: 33831358
[TBL] [Abstract][Full Text] [Related]
35. Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer.
Zhang P; Kawakami H; Liu W; Zeng X; Strebhardt K; Tao K; Huang S; Sinicrope FA
Mol Cancer Res; 2018 Mar; 16(3):378-389. PubMed ID: 29233910
[TBL] [Abstract][Full Text] [Related]
36. A Phase I Study of Dinaciclib in Combination With MK-2206 in Patients With Advanced Pancreatic Cancer.
Murphy AG; Zahurak M; Shah M; Weekes CD; Hansen A; Siu LL; Spreafico A; LoConte N; Anders NM; Miles T; Rudek MA; Doyle LA; Nelkin B; Maitra A; Azad NS;
Clin Transl Sci; 2020 Nov; 13(6):1178-1188. PubMed ID: 32738099
[TBL] [Abstract][Full Text] [Related]
37. Expression of classical human leukocyte antigen class I antigens, HLA-E and HLA-G, is adversely prognostic in pancreatic cancer patients.
Hiraoka N; Ino Y; Hori S; Yamazaki-Itoh R; Naito C; Shimasaki M; Esaki M; Nara S; Kishi Y; Shimada K; Nakamura N; Torigoe T; Heike Y
Cancer Sci; 2020 Aug; 111(8):3057-3070. PubMed ID: 32495519
[TBL] [Abstract][Full Text] [Related]
38. Antitumor T-cell Immunity Contributes to Pancreatic Cancer Immune Resistance.
Ajina R; Malchiodi ZX; Fitzgerald AA; Zuo A; Wang S; Moussa M; Cooper CJ; Shen Y; Johnson QR; Parks JM; Smith JC; Catalfamo M; Fertig EJ; Jablonski SA; Weiner LM
Cancer Immunol Res; 2021 Apr; 9(4):386-400. PubMed ID: 33509790
[TBL] [Abstract][Full Text] [Related]
39. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I.
Yamamoto K; Venida A; Yano J; Biancur DE; Kakiuchi M; Gupta S; Sohn ASW; Mukhopadhyay S; Lin EY; Parker SJ; Banh RS; Paulo JA; Wen KW; Debnath J; Kim GE; Mancias JD; Fearon DT; Perera RM; Kimmelman AC
Nature; 2020 May; 581(7806):100-105. PubMed ID: 32376951
[TBL] [Abstract][Full Text] [Related]
40. Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival.
Danilova L; Ho WJ; Zhu Q; Vithayathil T; De Jesus-Acosta A; Azad NS; Laheru DA; Fertig EJ; Anders R; Jaffee EM; Yarchoan M
Cancer Immunol Res; 2019 Jun; 7(6):886-895. PubMed ID: 31043417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
